Mechanistically, aberrant hyper-methylation of the promoter region might be responsible for decreased RAB11B-AS1 in osteosarcoma and RAB11B-AS1 exerts its effects in osteosarcoma via its sense-cognate gene RAB11B. Thus our study identified lnc-RAB11B-AS1 as a novel biomarker and therapeutic target for osteosarcoma. This evidence concerns the gene RAB11B and osteosarcoma.